Assembly Biosciences Inc has a consensus price target of $2.4, established from looking at the 8 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., HC Wainwright & Co., and Mizuho on April 1, 2024, March 24, 2023, and November 16, 2022. With an average price target of $1.5 between HC Wainwright & Co., HC Wainwright & Co., and Mizuho, there's an implied -88.30% downside for Assembly Biosciences Inc from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
04/01/2024 | ASMB | Buy Now | Assembly Biosciences | $12.82 | — | HC Wainwright & Co. | Ed Arce | — | Reiterates | → Neutral | Get Alert |
03/24/2023 | ASMB | Buy Now | Assembly Biosciences | $12.82 | -88.3% | HC Wainwright & Co. | Ed Arce | $30 → $18 | Maintains | Neutral | Get Alert |
11/16/2022 | ASMB | Buy Now | Assembly Biosciences | $12.82 | -76.6% | Mizuho | Salim Syed | $168 → $36 | Maintains | Buy | Get Alert |
10/24/2022 | ASMB | Buy Now | Assembly Biosciences | $12.82 | -84.4% | Truist Securities | Nicole Germino | $132 → $24 | Downgrade | Buy → Hold | Get Alert |
04/01/2022 | ASMB | Buy Now | Assembly Biosciences | $12.82 | -6.4% | Truist Securities | Nicole Germino | $180 → $144 | Maintains | Buy | Get Alert |
09/13/2021 | ASMB | Buy Now | Assembly Biosciences | $12.82 | -72.7% | HC Wainwright & Co. | Ed Arce | → $42 | Initiates | → Neutral | Get Alert |
09/02/2021 | ASMB | Buy Now | Assembly Biosciences | $12.82 | — | William Blair | Raju Prasad | — | Downgrade | Outperform → Market Perform | Get Alert |
05/10/2021 | ASMB | Buy Now | Assembly Biosciences | $12.82 | -45.4% | SVB Leerink | Geoffrey Porges | $96 → $84 | Maintains | Market Perform | Get Alert |
The latest price target for Assembly Biosciences (NASDAQ: ASMB) was reported by HC Wainwright & Co. on April 1, 2024. The analyst firm set a price target for $0.00 expecting ASMB to fall to within 12 months (a possible -100.00% downside). 1 analyst firms have reported ratings in the last year.
The latest analyst rating for Assembly Biosciences (NASDAQ: ASMB) was provided by HC Wainwright & Co., and Assembly Biosciences reiterated their neutral rating.
There is no last upgrade for Assembly Biosciences.
The last downgrade for Assembly Biosciences Inc happened on October 24, 2022 when Truist Securities changed their price target from $11 to $2 for Assembly Biosciences Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Assembly Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Assembly Biosciences was filed on April 1, 2024 so you should expect the next rating to be made available sometime around April 1, 2025.
While ratings are subjective and will change, the latest Assembly Biosciences (ASMB) rating was a reiterated with a price target of $0.00 to $0.00. The current price Assembly Biosciences (ASMB) is trading at is $12.82, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.